As I reflect on my year as ONS president from 2022–2023, my heart is filled with gratitude for the ONS Board of Directors members, staff, and members at large who contribute to the greater whole of what we know as ONS. Our organization is thriving thanks to teamwork at all levels. Ronald Reagan once quoted a sign he looked at daily that says, “There is no limit to what we can do or where we can go if we don’t mind who gets the credit.” Likewise, it’s truly a collective team that makes things happen in ONS.
They weren’t joking around when they said laughter is the best medicine! Laughter is a great form of stress relief and promotes your well-being, including your mental health.
Adding carboplatin to standard neoadjuvant chemotherapy for patients with triple-negative breast cancer improves complete response, event-free survival, and overall survival, researchers reported in study findings presented in abstract GS5-01 during the 2022 San Antonio Breast Cancer Symposium.
Caffeine is an integral part of daily life for many. Food and beverage manufacturers are capitalizing on our consumption beyond daily cups of coffee, putting the stimulant in everyday foods like donuts and bottled beverages, including water. However, too much caffeine may affect our health, leading the Caffeine Awareness Alliance to designate March as National Caffeine Awareness Month. You’re in good company if you use caffeine as a regular way to start your day, but here are some strategies if you want to cut back.
When the U.S. Food and Drug Administration (FDA) granted pemigatinib (Pemazyre®) a new indication in August 2022, it became the first targeted therapy approved for treatment of patients with relapsed or refractory myeloid or lymphoid neoplasms (MLNs) with fibroblast growth factor receptor (FGFR) 1 rearrangement. In 2021, FDA gave pemigatinib accelerated approval for patients with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or other rearrangement as detected by an FDA-approved test.
In February 2023, the Tandem Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR brought the latest cutting-edge science and technologies in hematopoietic cell transplantation and cellular therapy to nurses around the globe. Here are some of the highlights I experienced as an advanced practice provider (APP) in blood and marrow stem cell transplantation.
On March 22, 2023, the U.S. Food and Drug Administration granted accelerated approval to retifanlimab-dlwr (Zynyz®) for adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma.
An experimental HIV vaccine increased participants’ broadly neutralizing antibody (bnAb) precursor B cells that enable the body to develop bnAb-producing B cells and fight HIV, researchers reported in study results published in December 2022. The progress comes more than a decade after researchers at the National Institutes of Health’s National Institute of Allergy and Infectious Diseases Vaccine Research Center first discovered the rare class of antibodies.
From President Richard Nixon’s war on cancer in 1971 to President Joe Biden’s commitment to “ending cancer as we know it” in 2022, fighting the disease has been a bipartisan focus. Yet in that era, when cancer hit home, policymakers often hushed their own diagnoses. But times change, and many of today’s lawmakers are now boldly sharing their personal experiences with cancer as inspiration for action.
Schoolhouse Rock! celebrated its 50th anniversary in January 2023. The Saturday morning cartoons debuted in 1973 and brought school lessons on a variety of subjects, including government and democracy, to children through catchy yet educational lyrics and beats.